: Characterization of human embryonic stem cells with features of

: Characterization of human embryonic stem cells with features of neoplastic progression. Nat Biotechnol 2009,27(1):91–97.PubMed 117. Crooks VA, Snyder J: Foretinib manufacturer Regulating medical tourism. Lancet 2010,376(9751):1465–1466.PubMed 118. Barclay E: Stem-cell experts raise concerns about medical tourism. Lancet 2009,373(9667):883–884.PubMed 119. Lau D, Ogbogu U, Taylor B, Stafinski

T, Menon D, Caulfield T: Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell 2008,3(6):591–594.PubMed 120. Pepper MS: Cell-based therapy – navigating troubled waters. S Afr Med J 2010,100(5):286. 288PubMed 121. Woo P: Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2006,2(1):28–34.PubMed 122. Ringe J, Sittinger M: Tissue engineering in the rheumatic diseases. this website Arthritis Res Ther 2009,11(1):211.PubMed Protein Tyrosine Kinase inhibitor 123. Hayward K, Wallace CA: Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009,11(1):216.PubMed 124. Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, Van Laar J, Verburg R, Szer J, Taylor K, Joske D, et

al.: Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 2004,31(3):482–488.PubMed 125. Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M, Cannell P, Will R, Rule S, Joske D, et al.: A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Aprepitant Arthritis Rheum 2002,46(9):2301–2309.PubMed 126. De Kleer IM, Brinkman DM, Ferster A, Abinun M, Quartier P, Van Der Net J, Ten Cate R, Wedderburn LR, Horneff G, Oppermann J, et

al.: Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis 2004,63(10):1318–1326.PubMed 127. Jallouli M, Frigui M, Hmida MB, Marzouk S, Kaddour N, Bahloul Z: Clinical and immunological manifestations of systemic lupus erythematosus: study on 146 south Tunisian patients. Saudi J Kidney Dis Transpl 2008,19(6):1001–1008.PubMed 128. Ioannou Y, Isenberg DA: Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J 2002,78(924):599–606.PubMed 129. Traynor AE, Barr WG, Rosa RM, Rodriguez J, Oyama Y, Baker S, Brush M, Burt RK: Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 2002,46(11):2917–2923.PubMed 130. Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J, Verda L, Krosnjar N, Quigley K, Yaung K, et al.: Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006,295(5):527–535.PubMed 131.

Comments are closed.